Trials / Unknown
UnknownNCT02461407
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Gastric Cancer(ALTER0503)
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 378 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
| DRUG | Placebo | Placebo p.o. qd |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-06-03
- Last updated
- 2017-12-29
Locations
38 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02461407. Inclusion in this directory is not an endorsement.